You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》富瑞:藥明生物(02269.HK)在中國以外地區產能急升 已做好充分準備與客戶開展更多創新合作
阿思達克 01-11 14:26
富瑞發表研究報告指,藥明生物(02269.HK)最新與藥廠葛蘭素史克達成15億美元專利協議交易,及正在進行的在中國以外產能擴張,相信此能令集團巧妙地避開未來潛在地緣政治緊張局勢。該行重申對對藥明生物「買入」投資評級及目標價200元。 該行預計集團在中國以外的產能將從2021年的2.1萬升(佔產量14%)擴大逾四倍,並在2024年達到9.55萬升(佔產量22%)。從長遠來看,到2032年,集團計劃擁有中國境外產能21.55萬升(佔產量39%)。 富瑞表示,展望未來,隨著中國以外產能的增加,相對藥明生物已做好充分準備與客戶開展更多創新合作。隨著中國疫情形勢的改善、加息放緩以及基本面完整,投資者情緒應該會得到很大改善。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account